Overview
Background
Dr Brett Hughes graduated from the University of NSW with a Bachelor of Medical Science and Bachelor of Medicine and Surgery in 1997. He completed his postgraduate training in Canberra and Brisbane and was admitted as a Fellow of the Australian College of Physicians as a Specialist Medical Oncologist in 2005.
Dr Hughes is currently a Senior Staff Specialist Medical Oncologist at the RBWH and TPCH. He is also an Associate Professor at the University of Queensland since 2015. As the previous Clinical Director of Oncology (201-2017) and current Cancer Care Services Research lead at TPCH, Dr Hughes has established both an independent TPCH Oncology unit and continuing TPCH’s reputation as a lung cancer research centre of excellence.
Dr Hughes is an active senior member of the Thoracic Oncology Group Australasia (TOGA) and the Trans Tasman Radiation Oncology Group (TROG). He is also heavily involved in many pivotal multicentre trials of cancer therapy at both TPCH and RBWH with his principal research interests in Lung cancer, Head & Neck cancer, Mesothelioma, cutaneous SCC and Thyroid cancer. He has published over 100 peer review papers. Dr Hughes is also involved in undergraduate and post graduate teaching in his fields of research interest.
Availability
- Associate Professor Brett Hughes is:
- Available for supervision
Fields of research
Works
Search Professor Brett Hughes’s works on UQ eSpace
2021
Journal Article
Highly multiplexed digital spatial profiling of the tumor microenvironment of head and neck squamous cell carcinoma patients
Kulasinghe, Arutha, Taheri, Touraj, O'Byrne, Ken, Hughes, Brett G. M., Kenny, Liz and Punyadeera, Chamindie (2021). Highly multiplexed digital spatial profiling of the tumor microenvironment of head and neck squamous cell carcinoma patients. Frontiers in Oncology, 10 607349, 607349. doi: 10.3389/fonc.2020.607349
2021
Journal Article
CCTG BR34: a randomized phase 2 trial of Durvalumab and Tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC
Leighl, Natasha B., Laurie, Scott A., Goss, Glenwood D., Hughes, Brett G.M., Stockler, Martin, Tsao, Ming-Sound, Hwang, David M., Joubert, Phillipe, Kulkarni, Swati, Blais, Normand, Joy, Anil A., Mates, Mihaela, Rana, Punam, Yadav, Sunil K., Underhill, Craig, Lee, Christopher, Bradbury, Penelope A., Hiltz, Andrea, Dancey, Janet, Ding, Keyue and Vera-Badillo, Francisco (2021). CCTG BR34: a randomized phase 2 trial of Durvalumab and Tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC. Journal of Thoracic Oncology, 17 (3), 434-445. doi: 10.1016/j.jtho.2021.10.023
2020
Journal Article
CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells
Braun, Matthias, Aguilera, Amelia Roman, Sundarrajan, Ashmitha, Corvino, Dillon, Stannard, Kimberley, Krumeich, Sophie, Das, Indrajit, Lima, Luize G., Meza Guzman, Lizeth G., Li, Kunlun, Li, Rui, Salim, Nazhifah, Jorge, Maria Villancanas, Ham, Sunyoung, Kelly, Gabrielle, Vari, Frank, Lepletier, Ailin, Raghavendra, Ashwini, Pearson, Sally, Madore, Jason, Jacquelin, Sebastien, Effern, Maike, Quine, Brodie, Koufariotis, Lambros T., Casey, Mika, Nakamura, Kyohei, Seo, Eun Y., Hölzel, Michael, Geyer, Matthias ... Bald, Tobias (2020). CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells. Immunity, 53 (4), 805-823.e15. doi: 10.1016/j.immuni.2020.09.010
2020
Journal Article
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
Nowak, Anna K, Lesterhuis, W Joost, Kok, Peey-Sei, Brown, Chris, Hughes, Brett GM, Karikios, Deme J, John, Thomas, Kao, Steven C-H, Leslie, Connull, Cook, Alistair M, Pavlakis, Nick, Briscoe, Karen, O'Byrne, Kenneth J, Karapetis, Christos S, Lam, Wei-Sen, Langford, Ailsa, Yip, Sonia and Stockler, Martin R (2020). Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology, 21 (9), 1213-1223. doi: 10.1016/S1470-2045(20)30462-9
2020
Journal Article
Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)
Grob, Jean-Jacques, Gonzalez, Rene, Basset-Seguin, Nicole, Vornicova, Olga, Schachter, Jacob, Joshi, Abhishek, Meyer, Nicolas, Grange, Florent, Piulats, Josep M., Bauman, Jessica R., Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F. and Hughes, Brett G. M. (2020). Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). Journal of Clinical Oncology, 38 (25), 2916-2925. doi: 10.1200/JCO.19.03054
2020
Conference Publication
Abstract 3384: characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancer
Kulasinghe, Arutha, Kapeleris, Joanna, Kenny, Liz, Hughes, Brett, Warkiani, Majid, Vela, Ian, Thiery, Jean-Paul, O'Byrne, Ken and Punyadeera, Chamindie (2020). Abstract 3384: characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancer. AACR Annual Meeting 2020, Philadelphia, PA USA, 27-28 April 2020 and 22-24 June 2020. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/1538-7445.am2020-3384
2020
Conference Publication
Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC)
O'Leary, Connor, Fletcher, James, Yuile, Alexander, Xu, Wen, Ladwa, Rahul, McGrath, Margaret, Pavlakis, Nick, Hughes, Brett, McCaffery, Elizabeth and O'Byrne, Kenneth (2020). Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC). Medical Oncology Group of Australia Annual Scientific Meeting, Virtual, Australia, 14-21 August 2020. Chichester, West Sussex, United Kingdom: Wiley-Blackwell.
2020
Journal Article
Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma
Tang, Kai D., Vasani, Sarju, Menezes, Lilian, Taheri, Touraj, Walsh, Laurence J., Hughes, Brett G.M., Frazer, Ian H., Kenny, Liz, Scheper, Gert C. and Punyadeera, Chamindie (2020). Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma. Cancer Science, 111 (10) cas.14585, 3854-3861. doi: 10.1111/cas.14585
2020
Journal Article
Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE)
Ahern, Elizabeth, Allen, Michael J., Schmidt, Andrew, Lwin, Zarnie and Hughes, Brett G. M. (2020). Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE). Asia-Pacific Journal of Clinical Oncology, 17 (2) ajco.13350, e109-e116. doi: 10.1111/ajco.13350
2020
Journal Article
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412
Machiels, Jean-Pascal, Tao, Yungan, Burtness, Barbara, Tahara, Makoto, Licitra, Lisa, Rischin, Danny, Waldron, John, Simon, Christian, Gregoire, Vincent, Harrington, Kevin, Alves, Gustavo Vasconcelos, Figueiredo Lima, Iane Pinto, Pointreau, Yoann, M Hughes, Brett G., Aksoy, Sercan, Hetnal, Marcin, Ge, Joy Y., Brown, Holly, Cheng, Jonathan, Bidadi, Behzad and Siu, Lillian L. (2020). Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future oncology (London, England), 16 (18), 1235-1243. doi: 10.2217/fon-2020-0184
2020
Journal Article
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
Rischin, Danny, Migden, Michael R., Lim, Annette M., Schmults, Chrysalyne D., Khushalani, Nikhil I., Hughes, Brett G. M., Schadendorf, Dirk, Dunn, Lara A., Hernandez-Aya, Leonel, Chang, Anne Lynn S., Modi, Badri, Hauschild, Axel and Ulrich, Claas (2020). Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. Journal for immunotherapy of cancer, 8 (1) e000775. doi: 10.1136/jitc-2020-000775
2020
Journal Article
Weighted activity unit effect: evaluating the cost of diagnosis-related group coding
Tan, Joanne Y.-A., Senko, Clare, Hughes, Brett, Lwin, Zarnie, Bennett, Richard, Power, John and Thomson, Leah (2020). Weighted activity unit effect: evaluating the cost of diagnosis-related group coding. Internal Medicine Journal, 50 (4), 440-444. doi: 10.1111/imj.14373
2020
Journal Article
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer
Alexander, Marliese, Pavlakis, Nick, John, Thomas, O'Connell, Rachel, Kao, Steven, Hughes, Brett G.M., Lee, Adrian, Hayes, Sarah A., Howell, Viive M., Clarke, Stephen J., Millward, Michael, Burbury, Kate, Solomon, Benjamin and Itchins, Malinda (2020). A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer, 142, 34-40. doi: 10.1016/j.lungcan.2020.01.017
2020
Journal Article
An occult HPV-driven oropharyngeal squamous cell carcinoma discovered through a saliva test
Tang, Kai Dun, Vasani, Sarju, Taheri, Touraj, Walsh, Laurence J., Hughes, Brett G. M., Kenny, Lizbeth and Punyadeera, Chamindie (2020). An occult HPV-driven oropharyngeal squamous cell carcinoma discovered through a saliva test. Frontiers in Oncology, 10 408, 408. doi: 10.3389/fonc.2020.00408
2020
Journal Article
Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer
Ratnayake, Gishan, Shanker, Mihir, Roberts, Kate, Mason, Robert, Hughes, Brett G. M., Lwin, Zarnie, Jain, Vikram, O'Byrne, Kenneth, Lehman, Margot and Chua, Benjamin (2020). Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 16 (1), 56-62. doi: 10.1111/ajco.13242
2020
Journal Article
Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer
Fong, Lawrence, Hotson, Andrew, Powderly, John D., Sznol, Mario, Heist, Rebecca S., Choueiri, Toni K., George, Saby, Hughes, Brett G. M., Hellmann, Matthew D., Shepard, Dale R., Rini, Brian I., Kummar, Shivaani, Weise, Amy M., Riese, Matthew J., Markman, Ben, Emens, Leisha A., Mahadevan, Daruka, Luke, Jason J., Laport, Ginna, Brody, Joshua D., Hernandez-Aya, Leonel, Bonomi, Philip, Goldman, Jonathan W., Berim, Lyudmyla, Renouf, Daniel J., Goodwin, Rachel A., Munneke, Brian, Ho, Po Y., Hsieh, Jessica ... Miller, Richard A. (2020). Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. Cancer Discovery, 10 (1), 40-53. doi: 10.1158/2159-8290.CD-19-0980
2020
Journal Article
Outcomes of incidental pulmonary nodules in head-and-neck squamous cell cancer patients treated with curative intent
Tani, Daniel, Ladwa, Rahul, Xu, Wen, Lwin, Zarnie, Steinke, Karin and Hughes, Brett G. M. (2020). Outcomes of incidental pulmonary nodules in head-and-neck squamous cell cancer patients treated with curative intent. Journal of Head and Neck Physicians and Surgeons, 8 (1), 17-22. doi: 10.4103/jhnps.jhnps_39_19
2019
Journal Article
Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib
Chan, Sarah, Ahern, Elizabeth, Chaudhry, Sarah and Hughes, Brett (2019). Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib. BMJ case reports, 12 (12) e232868, e232868. doi: 10.1136/bcr-2019-232868
2019
Journal Article
EGFR mutations in lung cancer: not all equal in the eyes of the immune system?
Fong, Kwun M., Hughes, Brett G. M., Lwin, Zarnie and Yang, Ian A. (2019). EGFR mutations in lung cancer: not all equal in the eyes of the immune system?. Annals of Translational Medicine, 7 (S8) S326, S326-S326. doi: 10.21037/atm.2019.09.132
2019
Conference Publication
Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC)
Rischin, D., Khushalani, N. I., Schmults, C. D., Guminski, A., Chang, A. L. S., Lewis, K. D., Lim, A. M., Hernandez-Aya, L., Hughes, B. G. M., Schadendorf, D., Hauschild, A., Stankevich, E., Booth, J., Li, S., Chen, Z., Desai, J., Lowy, I., Fury, M. G. and Migden, M. R. (2019). Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC). Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva Switzerland, Dec 11-14, 2019. OXFORD: OXFORD UNIV PRESS.
Supervision
Availability
- Associate Professor Brett Hughes is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
The changing face of head and neck cancer: addressing and advancing best-practice nutritional care to improve outcomes for patients with human papillomavirus-associated disease
Associate Advisor
-
Doctor Philosophy
Developing predictive biomarkers for immunotherapy using deep spatial profiling
Associate Advisor
Other advisors: Associate Professor Arutha Kulasinghe
Completed supervision
-
2025
Doctor Philosophy
The investigation of the tumour microenvironment in head and neck squamous cell carcinoma to identify predictive biomarkers of response to immunotherapy
Associate Advisor
Other advisors: Dr Quan Nguyen, Associate Professor Arutha Kulasinghe
Media
Enquiries
For media enquiries about Associate Professor Brett Hughes's areas of expertise, story ideas and help finding experts, contact our Media team: